Fig. 4.
Fig. 4. Specific lysis of ALCL cell lines endogenously expressing NPM/ALK. / The p280-89–specific CTL lines generated from donors 01 and 02 (A,B) and p376-85–specific CTL line generated from donor 03 (C) efficiently recognize and lyse HLA-matched ALCL lymphoma cell lines (SU-DHL1 and SUP-M2) endogenously expressing NPM/ALK. Lysis was inhibited in the presence of anti-HLA-A2 mAb CR11.351 and no activity was detected against HLA-A2.1+ cell lines FM3 (melanoma), HCT-116 (colon carcinoma), and MCF-7 (breast carcinoma). Cytotoxic activity was determined in a standard 51Cr release assay at an E/T ratio of 50:1 (▪), 25:1 (■), 12:1(▤). Results of 1 representative experiment of at least 3 performed are shown.

Specific lysis of ALCL cell lines endogenously expressing NPM/ALK.

The p280-89–specific CTL lines generated from donors 01 and 02 (A,B) and p376-85–specific CTL line generated from donor 03 (C) efficiently recognize and lyse HLA-matched ALCL lymphoma cell lines (SU-DHL1 and SUP-M2) endogenously expressing NPM/ALK. Lysis was inhibited in the presence of anti-HLA-A2 mAb CR11.351 and no activity was detected against HLA-A2.1+ cell lines FM3 (melanoma), HCT-116 (colon carcinoma), and MCF-7 (breast carcinoma). Cytotoxic activity was determined in a standard 51Cr release assay at an E/T ratio of 50:1 (▪), 25:1 (■), 12:1(▤). Results of 1 representative experiment of at least 3 performed are shown.

Close Modal

or Create an Account

Close Modal
Close Modal